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Abstract
Background: Although the value of telemonitoring in heart failure patients is increasingly studied, little is known
about the value of the separate components of telehealth: ICT guided disease management and telemonitoring.
The aim of this study is to investigate the value of telemonitoring added to ICT guided disease management (DM)
on the quality and efficiency of care in patients with chronic heart failure (CHF) after a hospitalisation.
Methods/Design: The study is divided in two arms; a control arm (DM) and an intervention arm (DM+TM) in 10
hospitals in the Netherlands. In total 220 patients will be included after worsening of CHF (DM: N = 90, DM+TM: N =
130). Total follow-up will be 9 months. Data will be collected at inclusion and then after 2 weeks, 4.5 and 9 months.
The primary endpoint of this study is a composite score of: 1: death from any cause during the follow-up of the
study, 2: first readmission for HF and 3: change in quality of life compared to baseline, assessed by the Minnesota
Living with Heart failure Questionnaire. The study has started in December 2009 and results are expected in 2012.
Conclusions: The IN TOUCH study is the first to investigate the effect of telemonitoring on top of ICT guided DM
on the quality and efficiency of care in patients with worsening HF and will use a composite score as its primary
endpoint.
Trial registration: Netherlands Trial Register (NTR): NTR1898
Background
Heart failure (HF) is the most common hospital dis-
charge diagnosis in elderly patients [1]. Between the age
of 70 and 80 years the incidence of HF is 10 to 20%. HF
is associated with high mortality and morbidity, readmis-
sion rates and costs [1]. The readmission rates vary
between 25% and 50% within 6 months after the first
hospitalisation for HF, with a higher readmission rate
within the first month after discharge[2,3]. The costs
r e l a t e dt oH Fc o n t r i b u t et o1 - 2 %o fa l lh e a l t h c a r e
expenditures and are mainly the result of hospital stay
[4-6]. Because of an increasing shortage of resources, HF
is a major public health problem and therefore, a more
effective and efficient organisation of care for HF patients
needs to be reconsidered. A first step in organising treat-
ment and care for patients with chronic HF more effi-
ciently, was the implementation of specialised outpatient
HF clinics. In the recent European Society of Cardiology
(ESC) guidelines, HF management programmes are
strongly recommended for all patients with HF [1] and
HF clinics are considered as ‘usual care’ in several
European countries [7]. A widely used way to implement
HF management is the use of specific disease manage-
ment (DM) programs.
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age a chronic disease and to reduce hospital readmissions,
using a systematic approach to care and potentially
employing multiple treatment modalities [8]. Control and
cost effectiveness are substantial components of a DM pro-
gram. Randomised studies suggest that DM programs can
reduce readmissions for HF or cardiovascular disease with
30% [7,9,10] and significantly decrease mortality rates [11].
Yu et al [12] described that DM for HF patients, as recom-
mended by the ESC guidelines, [1] are effective in reducing
hospital readmissions and mo r t a l i t yr a t e[ 1 3 ] .H o w e v e r ,
inconsistent findings for readmission and mortality rates
have been found, probably due to the variety of compo-
nents and practical applications of the DM programs.
We recently reported results of the COACH study, a
study on the effect of a nurse led DM program on clinical
outcome [14], in which the positive effects of a DM pro-
gram on readmission were not confirmed, although there
was a trend to a reduction of mortality in the intervention
groups. The INH study [15] on the effect of DM in HF,
showed that a DM program compared to usual care could
reduce mortality but not hospitalisation rates. Important
components of this program were patient education, opti-
misation of medical therapy, psychosocial support and an
easy access to healthcare. An important aspect for the
treatment of HF patients is the prescription of HF related
medication at an optimal dose i.e. ACE-inhibitors, beta-
blockers, and aldosteronantagonists. The up titration to
optimal dosage is an aspect that often takes place at a HF
outpatient clinic. However, data from the Euro Heart Fail-
ure Survey showed us that guideline adherence for HF
medication although improving still is not optimal[16]. In
the IMPROVE study, dedicated HF clinics were associated
with greater use of cardiac resynchronisation therapy and a
better HF education, but not with better guideline adher-
ence to medication [17]. Health information technology,
integrated into a DM program might facilitate adherence
to guidelines of health professionals [18]. With new infor-
mation and communication technology (ICT), healthcare
providers can be supported in the diagnosis, treatment and
follow up of HF patients by expert computerised systems,
based on guidelines and protocols [19]. These systems can
be used to optimise medication according to guidelines
and provide structural support and education [20]. We
were the first to report promising findings on ICT guided
DM in terms of higher doses of recommended HF medica-
tion and lower readmissions [21,22]. Another promising
ICT tool is telemonitoring. Telemonitoring is often used to
monitor patients at home and guide patients to take action
in case of deterioration, but it also can be used to up-titrate
medication according to guidelines at distance [23]. There
is support that remote monitoring of patients with HF can
reduce hospitalisation and mortality rates, [24,25] however
results on clinical outcome and efficacy are inconclusive
and limited [26-28]. There are also recent study’st h a t
where not successful in their primary endpoints [29,30].
Furthermore, cost-effectiveness of these systems has not
been thoroughly evaluated. It can be concluded that the
overall effects of telemonitoring are inconclusive. To sum-
marise, due to a growing population of patients with HF
and an expected shortage of healthcare providers in the
near future, there is a need to seek to more cost effective
and efficient ways of providing optimal care for HF
patients, including a better adherence to guidelines. ICT
guided DM tools in combination with telemonitoring
could be of important value [31,32]. At the same time
there is substantional data that the adaptation and imple-
mentation of those systems is lacking [33]. The experiences
with such a system however are fragmented. User resis-
tance is described as a major obstacle in the adoption of
these computerised tools. More insight in user resistance
and experienced barriers in using ICT guided DM tools is
needed to successfully implementing such tools [34].
The IN TOUCH study will investigate the effect of
telemonitoring in addition to an ICT guided DM system
on the quality and efficiency of care for patients after
worsening HF. This is the first study investigating a
combination of two newly developed ICT interventions
in a group of chronic HF patients on clinical outcome,
adherence to guidelines, cost effectiveness and quality of
life.
This study will add important information to other tel-
emonitoring studies because of its strong commitment to
ICT guided DM, the chosen composite endpoint, a
strong focus on cost-effectiveness and the investigation
of the influence of user aspects as resistance and barriers
that accompany the use of modern healthcare related
ICT tools.
Methods/Design
Study hypothesis
Telemonitoring added to ICT guided DM improves
prognosis and quality of life in patients with HF com-
pared to ICT guided DM alone.
Aim of the study
The primary aim of this study is to assess the effect of
telemonitoring on top of an ICT guided DM system in
patients after worsening HF on the combined endpoint
of death, readmission and quality of life, compared to
patients treaded with ICT guided DM alone.
Secondary aims of the study are;
￿ To assess the effect of telemonitoring in addition
to an ICT guided DM system compared to an ICT
guided DM alone on the separate components of the
combined endpoint (death, readmission and quality
of life).
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DM with telemonitoring compared to ICT guided
DM alone.
Study design
A multicentre, randomised study in which in total 220
HF patients (NYHA II-IV) will be included. Patients will
be randomised to the ICT guided DM (control) arm
(N = 90) or into the ICT guided DM with telemonitor-
ing (intervention) arm (N = 130) (Figure 1).
Study population
All patients admitted to the intensive care/coronary care
unit or cardiology ward for HF or visiting the outpatient
clinic with worsening HF who need treatment or adjust-
ment of oral or intravenous diuretics, can be included in
the study. Other inclusion criteria are; evidence of struc-
tural underlying heart disease, left ventricular ejection
fraction ≤ 45% and age of at least 18 years. Reasons for
exclusion are myocardial infarction in the past month, car-
diac invasive intervention (percutaneous coronary inter-
vention, coronary arterial bypass, valve replacement, heart
transplantation, or cardiac resynchronisation therapy) in
the past 6 months or planned in the next 3 months, weight
> 200 kg, actual haemodialysis and the use of other tele-
monitoring systems (Table 1).
Primary endpoint
The primary endpoint of the study is a composite,
weighted score consisting ofv a l u e sf o rm o r t a l i t y ,H F
readmission and change in quality of life between end of
the study and baseline measured with the Minnesota
Living with HF Questionnaire (MLHFQ), adapted from
the A-HeFT study [35] (Table 2). A readmission for HF
is defined as an overnight hospital stay for HF or
directly related to HF. The readmissions for HF will be
blinded adjudicated by an endpoint committee. When
data on quality of life are missing, the worst-case score
for that component of the composite endpoint will be
used in the analysis.
Secondary endpoints
Secondary endpoints of the study are the separate com-
ponents of the primary endpoint. Other secondary end-
points are the total number and duration of all hospital
IN TOUCH TRIAL 
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Figure 1 Flowchart of the inclusion.
Table 1 In and exclusion criteria IN TOUCH
Inclusion criteria
Worsening HF defined as signs of fluid retention (peripheral oedema/
congestion)
needing an increase of the dose of diuretics (i.v. or oral)
Evidence for structural underlying heart disease
Documented reduced left ventricular ejection fraction (LVEF) ≤45%
18 years of age
Patients have to be able to understand content of and willing to
provide informed
consent.
Exclusion criteria
History of myocardial infarction in the previous month
Life expectation less than 1 year
Undergone cardiac invasive intervention within the last 6 months (PCI,
CABG, HTX, valve replacement, CRT implantation)
A planned procedure for PCI, CABG, HTX, CRT implantation or valve
replacement in the following 3 months
Evaluation for heart transplantation prior to or during the study
Weight more than 200 kilogram
The use of telemonitoring devices at home
Haemodialysis
Table 2 score system for primary endpoint IN TOUCH
End point Score
Death (at any time during study) -3
Survival to end of study 0
First readmission for heart failure -1
No readmission for heart failure 0
Change in quality of life at 9 months
Improvement ≥ 20 units +2
Improvement by 10 until 19 units +1
No improvement by -9 until +4 units 0
Worsening by +5 until +9 units -1
Worsening by ≥ 10 units -2
Possible score -6 to +2
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the criteria of the Guidelines Adherence Indicator-3 [36],
number of visits to the outpatient HF clinic, patient and
carer satisfaction, and cost-benefit ratio.
Ethics statement
On March 2009 this study design has became ethical
approval (M09.070323) given by the medical ethical com-
mission (MEC) of the medical university of Groningen
(UMCG).
The study has started (first patient) in December 2009.
Incremental cost-effectiveness ratio (ICER)
Costs A distinction will be made between intervention
costs and resource utilization costs. The intervention
costs consist of the costs of the DM system and the costs
of the telemonitoring devices and will be calculated as a
lump-sum over the study’s follow-up period. Resource
utilisation costs will be estimated by preparing a struc-
tured data collection form to collect detailed information
regarding scheduled and non-scheduled outpatient clinic
visits and hospital admissions (both HF and non-HF
related), ward type (e.g. intensive/coronary care unit, car-
diology, general internal medicine), and cardiovascular
procedures/operations. In addition, a patient question-
naire will be administered at 4.5 months and 9 months of
follow-up to collect complementary data on general prac-
titioner visits, home care utilization, and nursing home
admissions. Unit costs will be estimated by using the
Dutch guidelines for cost calculations and inflated to cur-
rent price levels using a general consumer price index.
Indirect costs, such as productivity losses, will not be
taken into account.
Quality Adjusted Life Years (QALYs)
Preference-based quality of life scores will be obtained
by administering the EQ-5D to all patients in both the
control group and the two intervention groups at base-
line, 4.5 months of follow-up, and 9 months of follow-
up. QALYs will subsequently be estimated by calculating
the area of the two trapezoids that result from linear
extrapolation of the three quality of life scores.
Cost-effectiveness
The balance between costs and effects will be assessed
by estimating the incremental cost per QALY gained
(ICER) for the intervention group compared with the
control group.
The time horizon over which the costs end effects of
the different treatment strategies will be compared is
equivalent to that observed during the period of the
study (i.e. no future projections will be made). Uncer-
tainty surrounding the ICER will be represented through
the use of cost-effectiveness acceptability curves, which
show, for each possible value of l (i.e. the societal
willingness-to-pay for one additional QALY), the prob-
ability that the intervention will be cost-effective.
Randomisation and data collection
Patients can be randomised during admission for HF,
and in case of worsening of HF at the outpatient clinic.
After confirmation of eligibility and written informed
consent, patients will be included into the study.
Patients will be randomised into the control or interven-
tion group. Patient characteristics and clinical variables
will be collected at baseline, and 2 weeks and 9 months
after discharge. Echocardiography, ECG, and laboratory
analysis will be performed at baseline during hospitalisa-
tion and at the end of the study. Quality of life as part
of the primary endpoint, measured with the Minnesota
Living with HF Questionnaire, will be collected at base-
line and at 9 months. Data about utilisation of resources
will be collected prospectively and comprise compo-
nents of direct costs, i.e. scheduled and non-scheduled
outpatient visits and hospital admissions.
Questionnaires about self-care behaviour, anxiety,
depression, compliance and medical technology assess-
ment (MTA) will be completed before discharge, and at
4.5 and 9 months (Table 3). Patients should be included
preferably as soon as possible but at least within a per-
i o do ft i m eo f1 4d a y sa f t e rd i s c h a r g eo ra f t e rt h ef i r s t
visit at the HF clinic with worsening HF.
Control group
ICT guided disease management system without
telemonitoring
Patients in this group receive care guided by an ICT
DM system. This system supports DM in a fully auto-
matic way, assisting the HF nurse to optimise pharma-
cological and non-pharmacological treatment, evaluate
treatment and adjust therapy to optimal levels, accord-
ing to current HF guidelines. The patient will receive
tailored education and counselling on the HF regimen,
symptom management and improvement of the phar-
macological and non pharmacological regimen.
The system mainly works as a computer decision sup-
port system. Based on the input of data from physical
examination, medical history, questionnaires and nursing
assessment, the system provides an advice to healthcare
providers according to the actual guidelines, including up
titration of HF medication to optimal doses.
Intervention group
ICT guided disease management with telemonitoring
Patients in the DM with telemonitoring group will be
treated with the above described ICT guided DM system
in combination with the following integrated telemoni-
toring devices that will be installed at the patients’ home;
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daily.
￿ blood pressure meter; patients will be instructed to
measure their blood pressure daily during up titration of
medication.
￿ ECG; patients have to perform an ECG twice a week
during up titration of beta-blockers.
￿ Health monitor; an interactive monitor collects data
from the weighing scale, blood pressure meter and ECG
device and will respond to the patients’ collected data.
Data will be directly transmitted to the DM system in
the hospital.
In case of a deviation of individualised predefined
ranges of weight, blood pressure or heart rhythm, the
health monitor will automatically generate supplemen-
tary questions directly to the patient to evaluate the
actual health situation. This data, measurements and sub-
jective patient information (predefined multiple choice
questions about HF symptoms) will be transferred to the
computerised DM in the hospital. Furthermore, the
health monitor will generate an advice about the non-
pharmacological treatment, for example regarding com-
pliance with fluid and sodium restriction. When the data
collected by the system deviates from predefined ranges,
the HF nurse will be informed automatically by mobile
phone and email. In that case, the HF nurse will contact
the patient by phone within two hours and further dis-
cusses symptoms and treatment. If data are outside any
reference range in combination with symptoms of dete-
rioration, patients will receive a message from the health
monitor that they will be contacted by the HF nurse.
Sample size calculation
Group sample sizes of 130 patients for the group treated
with telemonitoring and ICT guided DM and 90 patients
treated with ICT guided DM achieve 80% power to
detect superiority for telemonitoring using a one-sided,
two-sample t-test. The margin of equivalence is 0.0. The
true difference between the means is assumed to be 0.8.
The significance level (alpha) of the test is 0.025. The
data are drawn from populations with standard devia-
tions of - 2.0 and + 2.0. These figures are based on a pub-
lication [37] in which the effect of the combination of
isosorbidedinitrate and hydralazin was investigated in
patient with HF. In this study a difference of 0.4 was
demonstrated regarding the composite endpoint. Using
telemonitoring, we expect to find a larger difference espe-
cially in the QoL domain. It has to be addressed that no
information is currently available regarding the sensitivity
of the composite endpoint in a setting of new onset or
worsening HF patients.
Statistical analyses
The primary analysis will consist of a comparison of the
composite endpoint scores (Table 2) between ICT guided
DM in combination with telemonitoring, compared to
ICT guided DM without telemonitoring. The test will be
performed using a two-sample t-test, and two-sided 95%
confidence intervals will be constructed to describe the
treatment differences. An analysis of covariance will be
used to test for the treatment effect controlling for differ-
ent baseline characteristics. The results will be analysed
using an intention-to-treat analysis including the full set
of all randomised patients (primary efficacy population).
The primary efficacy population will be analysed at end-
point for composite score. Secondary endpoints involving
e.g. individual evaluation of deaths, hospitalisations, and
QOL after 9 months will be analysed over the entire
course of the study using appropriate methods. Two
types of economic analyses will be performed: these
include a cost-consequence analysis (CCA) for a disag-
gregated examination of resource costs and health
Table 3 Questionnaires and medical assessment used in the IN TOUCH
Questionnaires Baseline 2 weeks 4,5 month 9 month
Minnesota Living with Heart failure Questionnaire (MLHFQ) ￿￿
Revised Heart failure Compliance ￿￿
Disability Rating Index (VAS) ￿￿
Hospital Anxiety and Depression scale (HADS) ￿￿
Heart failure self-care behaviour scale (EHFScB) ￿￿
Medical technology assessment (MTA) ￿￿
EQ-5D ￿￿ ￿
Satisfaction questionnaire for patients and providers ￿
Medical assessment
NYHA score ￿￿ ￿
Echocardiography ￿
ECG ￿￿ ￿
Physical examination ￿￿ ￿
Laboratory tests ￿￿ ￿
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and cost-effectiveness analysis (CEA) in which the alter-
native intervention is examined in light of total cost per
unit of health outcome. Thus CCA will be performed
using the primary outcome of the study as the measure
of effectiveness. For this, the annual cost per patient trea-
ted to postpone or prevent one patient experiencing a
cardiovascular death or hospital admission for worsening
HF within the trial will be calculated [38]. For CEA, the
incremental cost-effectiveness ratios (ICERs), in terms of
cost per life year gained (LYG), will be estimated given
that there was a significant increase in survival with DM
and telemonitoring. CEA will not be performed in case
no reduction will be observed in cardiovascular or all
cause mortality. In case of missing data for the composite
end point score, the worst-case scenario will be assumed
for the primary analyses. Patients lost to follow-up will
be assumed to have died (-3) and those without a quality
of life measurement will be assigned the worst score (-2).
Study organisation
To include 220 patients in this study, 10 hospitals in the
Netherlands are participating in the IN TOUCH study.
The first patients are recruited in December 2009; the
end of the study is expected to be in September 2012.
Support and monitoring
The study is supported and monitored by the Trial Coor-
dination Centre (TCC), a contract research organisation
for clinical trials. Both the quality of the research data
and of the intervention will be structurally monitored
according to the GCP guidelines and TCC standards
(ISO 9000:2001).
Discussion
In the last decades, the introduction of ICT in healthcare
promised an improved quality of care while reducing work
load, and resulting in a more cost effective system. This
might be realised by the use of computer guided decision
support systems and telemonitoring [20,31,32,39,40]. The
IN TOUCH study is the first to investigate the effect of an
ICT guided DM system in combination with telemonitor-
ing in patients with HF. In recent years there has been
much research in the field of HF and DM. This has
resulted in the implementation of DM programmes in the
ESC guidelines [1]. The development of these guidelines
has enabled the creation of computer aided decision sup-
port programms [39]. In the recent guidelines the applica-
tion of ICT by DM programs is recommended. Although
there has been progression in the development of ICT
guided tools and these tools have become practical equip-
ment for enhanced decision making, healthcare providers
still experience great barriers in using and implementing
them for several, often unclear reasons [33,34].
Mortality and morbidity are important outcomes in
studies in HF patients. Quality of life becomes a more
important issue for patients and may be even more
important for them than survival or readmissions.
Therefore, a composite primary endpoint, including
quality of life, mortality and morbidity was chosen for
the IN TOUCH study. Another reason for this compo-
s i t ee n d p o i n ti st h a tf o rH Fah i g hs t a n d a r do fc a r e
has been established which makes it more difficult to
investigate the added effect of new therapeutic options.
Beside the statistical advantage of a composite end-
point, the study becomes less costly and results of pro-
mising new treatment may occur earlier with this
selected design. The strength of this study is the
important role of ICT guided DM, telemonitoring, the
composite endpoint, including quality of life, a strong
focus on cost effectiveness and the emphasis on
experienced user resistance and barriers regarding ICT
tools in healthcare.
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